BRIEF-Supernus reiterates guidance By: Reuters: Company News June 16, 2016 at 17:00 PM EDT * Remains in discussions with FDA regarding its supplemental new drug application, or SNDA, for migraine Read More >> Related Stocks: Supernus Pharm